Development of a Precision Toolkit for Controlling Genes in Clostridia, Which Comprise Half of the Gut Microbiome
Background
The gut microbiota in the human body exerts a strong influence on overall health, including immune system regulation, metabolic disorders, and cancer development. In particular, Clostridia are classified as a key species in the gut microbiome of healthy adults, accounting for approximately 50% of the microbial population. These microbes produce essential metabolites for host physiology, but researchers have long struggled to elucidate their specific mechanisms of action. This is partly due to the difficulty in culturing them and the fact that they are non-model microbes, making genetic manipulation challenging.
Until now, the academic community has largely relied on research focused on more easily manipulated model microbes such as Escherichia coli. Without the ability to directly control the genes of dominant gut microbes like Clostridia, establishing a clear causal relationship between specific metabolites they secrete and human diseases has remained elusive. Consequently, to fundamentally understand the microbial ecosystem and realize therapeutic genetic engineering, a versatile regulatory tool applicable to multiple species has been essential.
Key Discovery
A research team led by Professor Chun-Jun Guo at Weill Cornell Medicine has developed a modular genetic toolkit capable of artificially regulating Clostridia genes. The study was published in the journal Nature Biotechnology. The researchers first compared and analyzed 67 promoter sequences (transcription regulatory regions) within Clostridia strains, successfully identifying the most highly active constitutive promoters. By fusing these with gene switches that respond to chemical inducers, they completed an inducible promoter system in which gene expression is activated only in the presence of specific substances.
Furthermore, the team integrated CRISPR-Cas gene editing technology into this system, enabling the removal of specific microbial metabolic genes. To verify the effectiveness of this tool, in vivo experiments were conducted using mouse models. Targeted metabolites included TMA (Trimethylamine), associated with cardiovascular disease and anti-cancer immunity, and DCA (Deoxycholic acid), a representative secondary bile acid. The researchers successfully modulated the production levels of these substances by manipulating gene expression in the gut microbiota of mice. It was also confirmed that the metabolic production capacity could be fully and reversibly controlled depending on the presence or absence of the chemical inducer.
Significance and Prospects
This study has drawn significant attention from the academic community for providing a tool to elucidate the functions of Clostridia, a central component of the gut ecosystem that has been hindered by technical barriers. With the ability to freely generate strains with specific gene deletions, it is expected that subsequent research will increasingly clarify the correlations between gut microbial genes and human physiology. Moreover, the ability to regulate the production of target substances at desired times is anticipated to serve as a crucial foundation for the development of living therapeutics, which utilize microbes as therapeutic agents.
However, there remain challenges to be overcome before this technology can be safely applied in humans. It is still uncertain whether the regulatory switches will function without malfunction in the complex human gut microbiome, unlike in experimental mice. Another critical issue is the need to develop biological containment strategies to prevent genetically modified microbes from escaping into the external environment. The research team has stated their intention to continue follow-up studies, including additional validation using human-derived strains and ensuring safety, to address these limitations.
Nature Biotechnology, Published online: 25 August 2026; doi:10.1038/s41587-026-03269-zGenetic engineering tools are developed for nonmodel gut Clostridia, which influence human health.
Gut microbiome gene regulation technology has the potential to become a powerful therapeutic tool in future personalized medicine. A representative example is in cancer treatment scenarios. When administering immune checkpoint inhibitors to patients with pancreatic or breast cancer, this regulatory tool could be used to temporarily increase TMA production by Clostridia, thereby maximizing anti-cancer immune responses. After the completion of immunotherapy, the supply of the inducer could be halted to turn off gene expression, preemptively preventing the risk of blood clot formation caused by excessive TMA production. This marks the dawn of a new era in precision medicine, where microbial metabolic activity can be reversibly controlled in accordance with the stage of disease treatment.
Additionally, a treatment strategy could be envisioned to selectively block the DCA-producing gene in colorectal cancer patients to inhibit tumor growth. In patients with metabolic disorders or inflammatory bowel diseases caused by excess metabolite production, symptoms could be alleviated by blocking overactivated metabolic pathways. With the acquisition of the technological capability to precisely control microbes at the genetic level, the pharmaceutical industry is likely to re-evaluate microbes not merely as supplements, but as active candidates for new drug development.